EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.34M | 51.90M | 56.04M | 43.27M | 45.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.34M | 51.90M | 56.04M | 43.27M | 45.71M |
| Cost of Revenue | 203.76M | 185.60M | 161.66M | 133.85M | 109.28M |
| Gross Profit | -161.42M | -133.71M | -105.61M | -90.58M | -63.57M |
| SG&A Expenses | 56.91M | 55.35M | 55.76M | 55.28M | 53.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 260.67M | 240.95M | 217.41M | 189.13M | 162.68M |
| Operating Income | -218.33M | -189.05M | -161.37M | -145.85M | -116.97M |
| Income Before Tax | -205.57M | -175.20M | -146.69M | -130.78M | -103.49M |
| Income Tax Expenses | 183.00K | 183.00K | 90.00K | 90.00K | 83.00K |
| Earnings from Continuing Operations | -205.75 | -175.38 | -146.78 | -130.87 | -103.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -205.75M | -175.38M | -146.78M | -130.87M | -103.57M |
| EBIT | -218.33M | -189.05M | -161.37M | -145.85M | -116.97M |
| EBITDA | -216.25M | -187.14M | -159.64M | -144.31M | -115.78M |
| EPS Basic | -2.99 | -2.68 | -2.41 | -2.31 | -2.01 |
| Normalized Basic EPS | -1.87 | -1.67 | -1.50 | -1.44 | -1.25 |
| EPS Diluted | -2.99 | -2.68 | -2.41 | -2.31 | -2.01 |
| Normalized Diluted EPS | -1.87 | -1.67 | -1.50 | -1.44 | -1.25 |
| Average Basic Shares Outstanding | 274.42M | 258.70M | 241.98M | 225.12M | 202.74M |
| Average Diluted Shares Outstanding | 274.42M | 258.70M | 241.98M | 225.12M | 202.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |